230 related articles for article (PubMed ID: 32670888)
21. Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment.
Shrestha R; Prithviraj P; Bridle KR; Crawford DHG; Jayachandran A
J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33925488
[TBL] [Abstract][Full Text] [Related]
22. Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
Erös de Bethlenfalva-Hora C; Mertens JC; Piguet AC; Kettenbach J; Schmitt J; Terracciano L; Weimann R; Dufour JF; Geier A
Clin Sci (Lond); 2014 Feb; 126(3):243-52. PubMed ID: 23822114
[TBL] [Abstract][Full Text] [Related]
23. Epithelial-mesenchymal transition-related genes are linked to aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation.
Iwahashi S; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Takasu C; Saito Y; Yamada S
Cancer Lett; 2016 May; 375(1):47-50. PubMed ID: 26940140
[TBL] [Abstract][Full Text] [Related]
24. SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway.
Tang X; Liu B; Zhang C; Tang W; Liang S; Xiao Y; Deng R; Li Z
Front Oncol; 2021; 11():773045. PubMed ID: 34950583
[TBL] [Abstract][Full Text] [Related]
25. Insufficient Radiofrequency Ablation Treated Hepatocellular Carcinoma Cells Promote Metastasis by Up-Regulation ITGB3.
Zhang N; Ma D; Wang L; Zhu X; Pan Q; Zhao Y; Zhu W; Zhou J; Wang L; Chai Z; Ao J; Sun H; Tang Z
J Cancer; 2017; 8(18):3742-3754. PubMed ID: 29151962
[TBL] [Abstract][Full Text] [Related]
26. HMGB1 released from dead tumor cells after insufficient radiofrequency ablation promotes progression of HCC residual tumor via ERK1/2 pathway.
Zhou Y; Liu X; Zhang W; Xu Y; Zhang Q; Xiong S; Tang H; Luo B
Int J Hyperthermia; 2023; 40(1):2174709. PubMed ID: 36755436
[TBL] [Abstract][Full Text] [Related]
27. LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma.
Zhang PF; Wang F; Wu J; Wu Y; Huang W; Liu D; Huang XY; Zhang XM; Ke AW
J Cell Physiol; 2019 Mar; 234(3):2788-2794. PubMed ID: 30132868
[TBL] [Abstract][Full Text] [Related]
28. Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling.
Zhang N; Wang L; Chai ZT; Zhu ZM; Zhu XD; Ma DN; Zhang QB; Zhao YM; Wang M; Ao JY; Ren ZG; Gao DM; Sun HC; Tang ZY
PLoS One; 2014; 9(12):e115949. PubMed ID: 25542041
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.
Fukuda H; Numata K; Moriya S; Shimoyama Y; Ishii T; Nozaki A; Kondo M; Morimoto M; Maeda S; Sakamaki K; Morita S; Tanaka K
Radiology; 2014 Aug; 272(2):598-604. PubMed ID: 24689883
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
Kan X; Jing Y; Wan QY; Pan JC; Han M; Yang Y; Zhu M; Wang Q; Liu KH
Eur Rev Med Pharmacol Sci; 2015; 19(2):247-55. PubMed ID: 25683938
[TBL] [Abstract][Full Text] [Related]
32. Extracellular matrix collagen I promotes the tumor progression of residual hepatocellular carcinoma after heat treatment.
Zhang R; Ma M; Lin XH; Liu HH; Chen J; Chen J; Gao DM; Cui JF; Ren ZG; Chen RX
BMC Cancer; 2018 Sep; 18(1):901. PubMed ID: 30227844
[TBL] [Abstract][Full Text] [Related]
33. Involvement and Targeted Intervention of Mortalin-Regulated Proteome Phosphorylated-Modification in Hepatocellular Carcinoma.
Yang Y; Jin M; Dai Y; Shan W; Chen S; Cai R; Yang H; Tang L; Li L
Front Oncol; 2021; 11():687871. PubMed ID: 34395254
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
Feng X; Xu R; Du X; Dou K; Qin X; Xu J; Jia W; Wang Z; Zhao H; Yang S; Guo C; Liu T; Ma K
Am J Gastroenterol; 2014 Dec; 109(12):1891-9. PubMed ID: 25403366
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma.
Lu AQ; Lv B; Qiu F; Wang XY; Cao XH
Oncol Rep; 2017 Apr; 37(4):2071-2078. PubMed ID: 28350139
[TBL] [Abstract][Full Text] [Related]
36. Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy.
Yamada S; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Arakawa Y; Kanamoto M; Iwahashi S; Saito Y; Takasu C; Ishikawa D; Shimada M
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S436-42. PubMed ID: 24566861
[TBL] [Abstract][Full Text] [Related]
37. LINC00540 promotes sorafenib resistance and functions as a ceRNA for miR-4677-3p to regulate AKR1C2 in hepatocellular carcinoma.
Xu K; Wang X; Hu S; Tang J; Liu S; Chen H; Zhang X; Dai P
Heliyon; 2024 Mar; 10(5):e27322. PubMed ID: 38463802
[TBL] [Abstract][Full Text] [Related]
38. Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation.
Su T; Liao J; Dai Z; Xu L; Chen S; Wang Y; Peng Z; Zhang Q; Peng S; Kuang M
Oncogene; 2018 Jun; 37(26):3514-3527. PubMed ID: 29559743
[TBL] [Abstract][Full Text] [Related]
39. Large hepatocellular carcinoma with local remnants after transarterial chemoembolization: treatment by sorafenib combined with radiofrequency ablation or sorafenib alone.
Yuan H; Lan Y; Li X; Tang J; Liu F
Am J Cancer Res; 2019; 9(4):791-799. PubMed ID: 31106004
[TBL] [Abstract][Full Text] [Related]
40. Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma.
Obara K; Matsumoto N; Okamoto M; Kobayashi M; Ikeda H; Takahashi H; Katakura Y; Matsunaga K; Ishii T; Okuse C; Suzuki M; Itoh F
Hepatol Int; 2008 Mar; 2(1):116-23. PubMed ID: 19669287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
